- Alzheimer's Disease is one of the greatest challenges facing the world today, and a larger storm is coming.
- Cassava Sciences' Alzheimer's drug Simufilam has a unique method of action, and is consistently shown to be safe and effective.
- Simufilam has an excellent chance to be approved in 2021 as the first disease-modifying drug in Alzheimer's Disease history.
- Drastically underpriced from a series of events, Cassava Sciences could be the best-performing stock of 2021.
For further details see:
4 Reasons Cassava Sciences Could Be The Best-Performing Stock Of 2021